CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
Maribavir +1 moredrug
Likely dose
Maribavir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06034925
NCT06034925Phase 4Completed
CompareCT.gov

Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Medical University of South Carolina·interventional·Posted Sep 13, 2023·Updated Apr 30, 2026

In Brief

A Phase 4 clinical trial evaluating Maribavir and Valganciclovir for Transplant Complication and CMV. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransplant Complication, CMV
CountriesUnited States
CollaboratorsTakeda

Timeline

Phase 4CompletedFinished
202420252026
First PostedSep 13, 2023
Enrollment StartNov 6, 2023
Primary CompletionJun 30, 2025
Study CompletionAug 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.8 years ago

Interventions

Maribavirdrug

maribavir 400mg twice daily

Valganciclovirdrug

valganciclovir 900mg once daily